BPC-157 Oral vs Injection: Why This Peptide Survives Stomach Acid, and Where the Arginate Claim Came From

BPC-157 Oral vs Injection: Why This Peptide Survives Stomach Acid, and Where the Arginate Claim Came From

Almost every peptide is destroyed in the stomach, which is why almost none of them come in capsules. BPC-157 is the exception people cite, and the reason is written into its sequence. That much is well supported. What is much less supported is the claim, repeated on nearly every page selling the arginate salt, that switching the counterion makes it a thousand times more stable. I went looking for that number and could not find it in any journal.

Michael Phelps

Founder & Peptide Research Specialist, PrymaLab

Research reference · Last updated August 19, 2026 · ~19 min read

Why This Sequence Survives the Stomach

Peptides taken orally are usually destroyed before they get anywhere. Pepsin starts on them in the stomach, pancreatic proteases continue in the small intestine, and brush border peptidases finish the job. That is the whole reason insulin is injected.

BPC-157 is repeatedly described as an exception, and the explanation is specific enough to check.

The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Two things about that list matter.

First, there are no aromatic residues. No phenylalanine, no tyrosine, no tryptophan. Pepsin, the main gastric protease, cleaves preferentially at bonds adjacent to aromatic residues. A sequence containing none of them removes pepsin's preferred cut sites.^[1]

Second, there are four prolines out of fifteen residues, better than a quarter of the molecule. Proline's side chain loops back onto the backbone nitrogen, which rigidifies the local geometry and makes proline-containing bonds poor substrates for a wide range of peptidases.^[1]

Put those together and you have a molecule that is difficult to cut with the enzymes present in the gastrointestinal tract. Sikiric and colleagues reported BPC-157 remaining intact in human gastric juice for over 24 hours, which is unusual among peptides.^[1]

One connection worth making across our own library: the absence of aromatic residues also means BPC-157 has no efficient ultraviolet absorber, which affects how much light exposure matters during storage. That is covered in the storage and stability reference.

The Other Half of the Stability Question

Every page explaining why BPC-157 survives the stomach stops at the enzymes. That is half the problem, and the half it skips is the one the arginate claim is actually about.

A peptide sitting in gastric contents can be destroyed two ways that have nothing to do with each other. An enzyme can cut it, or the acid can cut it. Different chemistry, different rate-limiting steps, and different residues decide the outcome.

The features BPC-157 is famous for address the enzymatic route. No aromatic residues means no pepsin preference. Four prolines means poor substrate geometry for a wide range of peptidases. Both of those are about enzyme recognition.

Acid-catalysed hydrolysis works differently. It does not need an enzyme and it does not care about recognition sites. The dominant sequence determinant is aspartate, because the aspartate side chain carboxyl can attack its own backbone and cleave the chain, and that reaction requires the carboxyl to be protonated, which is why the rate climbs as pH drops. Aspartyl bonds are the classic weak point in acidic conditions, with Asp-Pro the most labile and Asp-Gly close behind.

Now index the sequence. G1 E2 P3 P4 P5 G6 K7 P8 A9 D10 D11 A12 G13 L14 V15.

Two aspartates, adjacent, sitting in the middle of a molecule whose selling point is acid stability.

I want to be careful about what this does and does not mean, because it would be easy to read it as a debunking and it is not one. BPC-157 does not have an Asp-Pro bond, which is the worst case. And the gastric juice observation is an empirical result: whatever acid hydrolysis was going to happen over those 24 hours already happened during the experiment, and the peptide was reported intact anyway.^[1] The measurement answers the question directly and my sequence analysis does not override it.

What it changes is the explanation. The mechanism story people repeat, no aromatics plus lots of proline, accounts for the enzymatic half of a result that has two halves. The acid half came out fine for reasons the standard explanation does not cover, and as far as I can tell nobody has published which reasons.

This is also, finally, where the PDA number starts to make sense as a piece of marketing. pH 3.0 is exactly the condition under which aspartyl hydrolysis matters. Somebody choosing that pH for a stability comparison chose the right pH. Which makes it more frustrating rather than less that the comparison has never appeared in a journal, because it is the correct experiment and the result would be worth knowing.

The Drinking Water Studies

Gastric stability tells you the molecule survives. It does not tell you that anything crosses into circulation, and those are different claims that get run together constantly.

The evidence that oral delivery produces systemic effects comes from rodent work. The result usually cited is Cerovecki and colleagues in 2010: oral BPC-157 delivered in drinking water produced ligament healing outcomes equivalent to intraperitoneal injection at 10 micrograms per kilogram.^[2]

Equivalent outcomes by two routes is a meaningful result and it is the strongest single piece of evidence for oral BPC-157. It is also worth being precise about what it does not include: no bioavailability figure was quantified.^[2] The study measured healing, not plasma concentration. So the honest reading is that enough got through to produce an effect in that model at that dose, and the fraction absorbed remains unmeasured.

Other work in the Sikiric programme reported systemic effects from oral administration by gavage or in drinking water across several models including tendon healing and brain injury recovery.^[1][2] The same caveat about the source concentration of that literature applies here as everywhere else with this compound: a large proportion traces to a small set of connected groups, and independent replication is thinner than the citation count implies.

There is also a design detail in the drinking water approach that deserves mention. Delivering a compound in drinking water means continuous low-level exposure across the animal's drinking behaviour, which is a different exposure profile from a single bolus injection. Comparing "oral" to "injection" in that setup compares two things that differ in more than route.

Pentadeca Arginate, and the Missing Citation

This is the section I actually wanted to write, and it is the reason this article exists in its current form.

Over the last couple of years a product called Pentadeca Arginate, usually abbreviated PDA, has appeared everywhere, marketed as a next-generation successor to BPC-157. Search volume for "PDA peptide" is real and growing.

Here is what PDA is. It is GEPPPGKPADDAGLV. The same fifteen residues in the same order. The only difference is the counterion: arginine instead of the conventional acetate.^[3]

That is the whole difference. Same peptide, different salt.

The claim

The figure attached to PDA in compounding pharmacy marketing is that the arginate counterion makes it 1,000 times more stable than BPC-157 acetate at pH 3.0, the approximate acidity of stomach contents.^[3]

I went looking for the source. That specific stability claim has not been published in any peer-reviewed journal.^[3] It circulates as a marketing figure, gets repeated across supplier pages, and acquires the appearance of a finding through repetition rather than through anyone having published the measurement.

I am not saying the arginate salt is identical to the acetate in every respect. Counterions genuinely affect solubility, hygroscopicity and sometimes solid-state stability. I am saying that a precise, dramatic, three-order-of-magnitude number is exactly the kind of claim that should have a citation, and this one does not have one I can find.

The part that follows from it

Here is the consequence nobody selling PDA mentions. The published BPC-157 research used the acetate.^[3] The gastric juice stability work, the drinking water studies, the tendon and ligament models, the gut protection work: acetate, in the overwhelming majority.

So a page selling PDA on the strength of the BPC-157 literature is citing evidence generated with the other salt form, while simultaneously arguing that the salt form makes a thousandfold difference. Those two positions cannot both be load-bearing. Either the counterion matters enormously, in which case the acetate literature does not transfer cleanly, or it does not matter much, in which case the marketing claim is inflated.

What a Counterion Actually Does

Since the previous section leans on the distinction, it is worth being clear about what changing a salt form does and does not do, because plenty of people encountering the term for the first time reasonably assume it means a modified molecule.

A synthetic peptide with basic residues, and BPC-157 has a lysine, comes off the purification process as a salt. The counterion is whatever acid was in the final step, usually trifluoroacetic acid or acetic acid. It is associated with the peptide ionically rather than covalently, and it is not part of the molecule.

What the counterion can affect: solubility, how readily the lyophilised powder takes up moisture from air, the pH of a solution when you reconstitute in unbuffered water, and in some cases solid-state stability. Those are real and they are formulation properties.

What it does not affect: the amino acid sequence, the molecular mass of the peptide itself, or the receptor interactions. Dissolve either salt and you have the same peptide in solution, plus different spectator ions.

There is a practical consequence for anyone comparing suppliers on price. Counterion content changes what a stated milligram figure contains. A vial labelled 5mg of peptide may be 5mg of the salt, of which the peptide is a lower net figure, and the difference between an acetate and a trifluoroacetate salt is not trivial. This is the single most common source of apples-to-oranges pricing in the whole category, and it applies regardless of which salt you prefer.

Choosing a Route for a Research Question

The consumer framing of this question is "which is better." For research design the useful framing is "where is the effect being measured."

Oral delivery puts a high concentration in the gut lumen. If the model is gastrointestinal, that is the target tissue and oral delivery reaches it at concentrations no systemic route can match. A large fraction of the original BPC-157 work was gastrointestinal, which is not accidental given where the peptide was isolated from.

Injection removes absorption as a variable. If the target tissue is a tendon in a limb, absorption uncertainty sits between the dose and the effect, and a parenteral route eliminates it. When the question is about systemic distribution rather than gut-local action, that matters.

The comparison people want, which is a bioavailability percentage letting you convert one route into the other, does not exist for this compound in humans. What exists is one rodent study reporting equivalent outcomes at a specified dose in one model.^[2]

PrymaLab supplies BPC-157 as 5mg and 10mg lyophilised reference material, as 500mcg capsules, and in nasal spray and autoinjector formats.

What a Capsule Adds That a Vial Does Not

A short section, because there is less to say here than the search volume implies.

The peptide in a capsule is the same molecule as the peptide in a vial. What differs is everything around it: a shell, usually gelatin or HPMC, plus fillers, flow agents and whatever else the encapsulation process requires.

Two questions worth asking any supplier of peptide capsules. Does the certificate of analysis describe the finished capsule or the raw peptide before encapsulation? Those are different tests and the second is much more common. And what is the actual peptide content per capsule after excipients and counterion are accounted for?

Capsules also remove the reconstitution step, which removes the point at which degradation accelerates. A lyophilised peptide inside a capsule is still a lyophilised peptide, so the storage clock behaves like powder rather than like solution. That is a real advantage of the format and it is rarely the one that gets advertised.

The Combination Capsule Problem

BPC-157 and TB-500 capsules sell well and I stock them. The oral case for the first compound does not automatically extend to the second, and I have not seen a single page that says so.

TB-500 as supplied is usually the seven-residue fragment Leu-Lys-Lys-Thr-Glu-Thr-Gln, the actin-binding region of thymosin beta-4, rather than the full 43-residue protein. Look at residues two and three.

Two lysines, adjacent.

Trypsin cleaves on the carboxyl side of lysine and arginine. That is not a preference the way pepsin prefers aromatics. It is trypsin's defining specificity, and trypsin is one of the main endopeptidases waiting in the small intestine.

So a combination capsule holds one peptide that happens to lack the preferred cut site of every major gastrointestinal protease, and one peptide that carries the recognition site of the principal intestinal endopeptidase twice, side by side, near its N-terminus.

There is a known exception that would help if it applied: Lys-Pro bonds resist trypsin, because proline in the following position blocks the cleavage. In LKKTETQ the second lysine is followed by threonine, not proline. The exception does not apply.

The naming ambiguity makes this worse rather than better. If a vial or capsule labelled TB-500 contains full-length thymosin beta-4 instead of the fragment, you have a 43-residue protein with more lysines and arginines, not fewer, and the same argument applies with more force. Either way the component is a good trypsin substrate. That labelling problem is covered in the storage and stability reference, where it has consequences for shelf life too.

Where enteric coating fits

This produces a formulation point that runs against the marketing on most combination products.

Enteric coatings dissolve above roughly pH 5.5, which protects an acid-labile compound by holding it intact through the stomach and releasing it in the small intestine. For BPC-157 on its own, that is close to pointless, because gastric survival is the one thing the compound is documented to do well, and the small intestine is where the pancreatic proteases are.

For the TB-500 component, an enteric coating moves the release point toward the compartment with the most trypsin in it. That is the wrong direction.

I am not going to pretend I have a formulation answer to this. The point is narrower: a combination capsule is two different absorption problems in one shell, and any coating decision helps one component at the other's expense. If your research question concerns the TB-500 component specifically, the oral format carries a difficulty the BPC-157 component does not, and no supplier page I have read acknowledges it.

Side by Side

Regulatory Position in 2026

BPC-157's status moved twice in the last three years and most content on the compound is out of date.

On 29 September 2023 the FDA added BPC-157 to Category 2 of the interim 503A bulk drug substances list, citing potential immunogenicity for certain routes and difficulty characterising peptide impurities and the active ingredient.^[4] That was a statement about insufficient information rather than demonstrated harm, and it is routinely misreported as a ban on safety grounds.

In April 2026 the FDA removed BPC-157 from Category 2, which moved it from prohibited back to unresolved.^[5]

On 23 July 2026 the Pharmacy Compounding Advisory Committee voted 8 to 6 with one abstention to recommend BPC-157 for the 503A affirmative list.^[6] KPV and TB-500 passed by the same margin. DSIP was rejected 6 to 7 the following day.^[6]

Those votes are advisory and not binding, rulemaking has not completed, and none of the recommended compounds is legal to compound today.^[6] For laboratory reference material this changes nothing directly, because 503A governs pharmacy compounding rather than research supply.

What Research Has Not Established

No human pharmacokinetic study has been published for BPC-157 by any route. There is no oral bioavailability percentage, no injection comparison in humans, and no completed controlled human efficacy trial for any indication.

No peer-reviewed comparison of the acetate and arginate salt forms has been published, which means the 1,000-fold figure is unsupported and so is any confident statement in the opposite direction. I do not know that the arginate is no better. I know the number being quoted has no published basis.

The 2010 drinking water result is one study, in one model, at one dose, measuring healing outcomes rather than plasma concentration. It supports the claim that oral delivery can produce systemic effects in rodents. It does not support a conversion factor between routes.

What is well established: the sequence, the absence of aromatic residues, the proline content, the reported gastric juice stability, and the regulatory timeline above. Those are checkable. Almost everything else in this category is inference stacked on a literature concentrated in a small number of groups.

How to Read the Certificate

Four things to look for on a BPC-157 certificate of analysis, in rough order of how often they are missing.

The counterion, and the salt-corrected peptide content. Without both, a milligram figure is not comparable between suppliers.

Whether the analysis describes the finished dosage form or the raw peptide, if you are buying capsules.

And identity by mass spectrometry rather than purity alone. BPC-157 has no methionine or cysteine, so oxidation is not the usual concern here, but the aspartate-rich region means hydrolysis products are worth resolving.

At PrymaLab, research peptides are characterised with HPLC and mass spectrometry verification and independent third-party testing.

Frequently Asked Questions

Does oral BPC-157 actually work?

In rodents, reasonably well supported. Cerovecki and colleagues reported in 2010 that drinking water delivery matched intraperitoneal injection for ligament healing at 10 mcg/kg. No bioavailability figure was quantified and no human data exists.

Why would a peptide survive stomach acid at all?

Sequence composition. GEPPPGKPADDAGLV has no aromatic residues, which removes pepsin's preferred cut sites, and four prolines out of fifteen, which obstruct many peptidases.

Does BPC-157 contain acid-sensitive residues?

Two. Acid hydrolysis is driven mainly by aspartate, and BPC-157 has aspartate at positions 10 and 11. It avoids the worst case, an Asp-Pro bond. Enzymatic resistance and acid resistance are separate properties decided by different residues, and the standard explanation covers only the first.

Are BPC-157 and TB-500 equally suited to capsule form?

No. TB-500 is usually supplied as LKKTETQ, which carries two adjacent lysines, and trypsin cleaves specifically after lysine and arginine. The Lys-Pro exception does not apply because the second lysine is followed by threonine.

What is Pentadeca Arginate?

The same peptide, GEPPPGKPADDAGLV, with an arginine counterion instead of acetate. The sequence is identical.

Is the arginate really more stable?

The "1,000 times more stable at pH 3.0" figure appears in compounding pharmacy marketing and has not been published in any peer-reviewed journal. The published research used the acetate.

Should you use oral or injectable in research?

Depends where the effect is measured. Oral puts high concentration in the gut lumen. Injection removes absorption as a variable. Neither has published human pharmacokinetics.

Are capsules the same as the injectable material?

Same molecule, plus a shell and excipients. Ask whether the certificate describes the finished capsule or the raw peptide.

Is BPC-157 approved for human use?

No. Research use only. It was on 503A Category 2 from September 2023, removed April 2026, and recommended for the affirmative list by an 8 to 6 advisory vote in July 2026.

References